For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Hybridon, Inc.

Calculating rank

USPTO Granted Patents = 98

% Expired Patents = 1.0

CIPO Patents = 3

Trademarks = 3

Forward Citations = 3,625

Loading Chart...

Loading Chart...

72 inventors (with patents filed for the assignee):

Sudhir Agrawal (53 out of 153 patents)

Radhakrishnan P Iyer (13 out of 38 patents)

Dong Yu (11 out of 66 patents)

4. John Goodchild (11 out of 11 patents)

5. Gregory S Robinson (11 out of 12 patents)

6. Ivan Habus (11 out of 11 patents)

7. Jin-Yan Tang (8 out of 17 patents)

8. Ekambar R Kandimalla (6 out of 78 patents)

9. Qiuyan Zhao (6 out of 15 patents)

10. Ruiwen Zhang (6 out of 6 patents)

11. Aharon S Cohen (6 out of 15 patents)

12. Thomas E Leonard (6 out of 6 patents)

13. Eric Von Hofe (5 out of 7 patents)

14. Theresa Devlin (5 out of 5 patents)

15. Bruce L Frank (4 out of 4 patents)

Core Competencies:

Oligonucleotides

Hepatitis B

Tumor Growth

Gene Expression

Antisense

VEGF

CpG

Drug Resistance

Metastatic Cancer

Synthesis

Immunostimulation

Nucleic Acid

98 patents: Sort by Forward Citations

1. 6984729 - Oligonucleotides specific for hepatitis B virus (2006-01-10),

2. 6946447 - MDM2-specific antisense oligonucleotides (2005-09-20),

3. 6936593 - Method of down-regulating gene expression (2005-08-30),

4. 6815429 - Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides (2004-11-09),

5. 6667293 - Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response (2003-12-23),

6. 6649596 - Modified VEGF Oligonucleotides for Inhibition of tumor growth (2003-11-18),

7. 6645943 - Method of down-regulating gene expression (2003-11-11),

8. 6624293 - Modified protein kinase A-specific oligonucleotides and methods of their use (2003-09-23),

9. 6608035 - Method of down-regulating gene expression (2003-08-19),

10. 6605708 - Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom (2003-08-12),

11. 6531589 - Base protecting groups and synthons for oligonucleotide synthesis (2003-03-11),

12. 6509459 - Base protecting groups and rapid process for oligonucleotide synthesis (2003-01-21),

13. 6509149 - HPV-specific oligonucleotides (2003-01-21),

14. 6489464 - Branched oligonucleotides as pathogen-inhibitory agents (2002-12-03),

15. 6489304 - Hyperstructure-forming carriers (2002-12-03),

Company Overview

Hybridon, Inc., based in Cambridge, MA, specializes in the development of innovative oligonucleotide technologies. The company focuses on advancing therapeutic applications related to gene expression modulation, particularly in areas such as Hepatitis B treatment, tumor growth inhibition, and addressing drug resistance. Hybridon's research encompasses a range of core topics including antisense mechanisms, VEGF targeting, and CpG motifs, positioning it at the forefront of genetic and molecular medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

98 Patents

#31 in Cambridge, MA

#214 in Massachusetts

#3,859 in US

#7,930 in the World

Cambridge, MA, United States of America

Hybridon, Inc.

Forward Citations = 3,625

72 inventors:

Sudhir Agrawal (53 out of 153 patents)

Radhakrishnan P Iyer (13 out of 38 patents)

Dong Yu (11 out of 66 patents)

4. John Goodchild (11 out of 11 patents)

5. Gregory S Robinson (11 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hybridon, Inc.. Retrieved from https://idiyas.com/company/hybridon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…